Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects

[1]  S. Higuchi,et al.  Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects , 1996 .

[2]  A. D. Rodrigues,et al.  Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.

[3]  J. Gerloff,et al.  Pharmacokinetics and absolute bioavailability of lansoprazole , 1996, European Journal of Clinical Pharmacology.

[4]  L. Bertilsson,et al.  Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.

[5]  L. Bertilsson,et al.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. , 1995, British journal of clinical pharmacology.

[6]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[7]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[8]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. , 1994, British journal of clinical pharmacology.

[9]  S. Kitareewan,et al.  Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. , 1994, Biochemistry.

[10]  D. Faulds,et al.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. , 1992, Drugs.

[11]  J. Idle,et al.  Pharmacogenetic Phenotyping and Genotyping , 1994, Clinical pharmacokinetics.

[12]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.

[13]  S. Wrighton,et al.  Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.

[14]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.

[15]  K. Chiba,et al.  Incidence of S‐mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics , 1992, Clinical pharmacology and therapeutics.

[16]  D. Faulds,et al.  Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. , 1992, Drugs.

[17]  T. Yashiki,et al.  High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. , 1991, Journal of chromatography.

[18]  H. Satoh,et al.  Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. , 1991, Japanese journal of pharmacology.

[19]  L. Bertilsson,et al.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. , 1990, Therapeutic drug monitoring.

[20]  H. Satoh,et al.  Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. , 1990, The Journal of pharmacology and experimental therapeutics.

[21]  K. Brøsen.  Recent Developments in Hepatic Drug Oxidation Implications for Clinical Pharmacokinetics , 1990, Clinical pharmacokinetics.

[22]  U. Meyer,et al.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. , 1988, Biochemistry.

[23]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[24]  W. Kalow,et al.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. , 1985, British journal of clinical pharmacology.